iRadimed
IRMD
79 hedge funds and large institutions have $152M invested in iRadimed in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 35 increasing their positions, 21 reducing their positions, and 13 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 21
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.81% less ownership
Funds ownership: 44.84% → 44.04% (-0.81%)
8% less funds holding
Funds holding: 86 → 79 (-7)
10% less capital invested
Capital invested by funds: $169M → $152M (-$16.9M)
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$1.73M |
| 2 |
NTCM
Nine Ten Capital Management
Chicago,
Illinois
|
+$1.6M |
| 3 |
BCM
Bares Capital Management
Austin,
Texas
|
+$1.35M |
| 4 |
Millennium Management
New York
|
+$1.24M |
| 5 |
BlackRock
New York
|
+$648K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCG
Resource Consulting Group
Orlando,
Florida
|
-$3.85M |
| 2 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$1.72M |
| 3 |
Calamos Advisors
Naperville,
Illinois
|
-$1.72M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$1.59M |
| 5 |
Renaissance Technologies
New York
|
-$921K |
IRMD Hedge Fund Activity: Q4 2022 in Review
79 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in iRadimed (IRMD) for Q4 2022, worth a combined $152M — down 10% from $169M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of IRMD and 7 opened new positions — a net loss of 6 holders — while 21 trimmed existing stakes and 35 added.
The largest buyer was Soleus Capital Management, adding an estimated $1.73M. The largest seller was Resource Consulting Group, exiting entirely with an estimated $3.85M sold.
- 79 institutional investors held iRadimed (IRMD) as of Q4 2022, down from 86 in Q3 2022.
- Funds reported $152M of iRadimed stock for Q4 2022, down 10% quarter-over-quarter.
- 7 funds opened new iRadimed positions in Q4 2022 and 13 closed out, a net change of -6 holders.
- The largest iRadimed buyer in Q4 2022 was Soleus Capital Management, an estimated $1.73M added.
- The largest iRadimed seller in Q4 2022 was Resource Consulting Group, an estimated $3.85M sold.
Based on aggregated 13F filings for Q4 2022.